EUCTR2014-005189-31-DK进行中（未招募）1 期
Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”. - DARA for myeloma
Dept Hematology SLB Vejle0 个研究点目标入组 60 人开始时间: 2014年12月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients that have been enrolled into a clinical trial MMY3003 for treatment of multiple myeloma
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Patients not elegible for MMY3003
研究者
相似试验
已完成
1 期
Specific immunotherapy for multiple myeloma using vaccine complex consisting of idiotype protein and monosodium urate crystals (phase I study)multiple myelomaJPRN-UMIN000002290ational Hospital Organization Awara Hospital18
进行中（未招募）
1 期
Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosisEUCTR2008-002626-11-SEDept of Neurology
招募中
不适用
Individualized therapy in patients with primary membranous nephropathyprimary membranous nephropathyNL-OMON28712Radboud UMC Nijmegen100
招募中
不适用
Monoclonal antibodies as a treatment for Lassa virusviral hemorrhagic feverLassa Virus Infection10047438NL-OMON53355Academisch Medisch Centrum5
已完成
1 期
A combination immunotherapy for the patients with advanced or metastatic solid cancersolid cancerJPRN-UMIN000020440Yamaguchi university Graduate School of Medicine17